P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial

• Joseph F Merola,
• Subhashis Banerjee,
• Eric Morand,
• Piotr Leszczyński,
• Marilyn Pike,
• Ronald F van Vollenhoven,
• Coburn Hobar,
• Kathryn H Dao,
• Samantha Pomponi,
• Matthew J Colombo,
• Ravi Koti,
• Thomas Wegman

Affiliations

Joseph F Merola

Division of Rheumatology, Department of Medicine, Harvard Medical School, Brigham and Women`s Hospital, Boston, Massachusetts, USA

Subhashis Banerjee

7 Bristol Myers Squibb, Princeton, New Jersey, USA

Eric Morand

1Monash University, Melbourne, VIC, Australia

Piotr Leszczyński

12Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, Poland

Marilyn Pike

6Massachussetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Ronald F van Vollenhoven

1Dept. of Rheumatology and Immunology, Amsterdam UMC, Amsterdam, the Netherlands

Coburn Hobar

2Clinical Development, Bristol Myers Squibb, USA

Kathryn H Dao

3Dept. of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, TX, USA

Samantha Pomponi

6Bristol Myers Squibb, Princeton, NJ, USA

Matthew J Colombo

6Bristol Myers Squibb, Princeton, NJ, USA

Ravi Koti

7Syneos Health, Morrisville, NC, USA

Thomas Wegman

6Bristol Myers Squibb, Princeton, NJ, USA